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Objectives: The fast-rising rate of diabetes incidents is a growing concern in Central Asian 
countries. This article reviews the current understanding of type 2 diabetes etiology, progression 
and treatment options along with opportunities for utilizing Avicenna’s legacy in developing 
novel botanical therapeutics. Methods: Analysis of relevant publications, including a variety of 
Avicenna’s work in Arabic, English and Russian. Results: With conventional treatment strategy 
shifting from single-component drugs aimed at one target to multitherapeutic combinations 
addressing the complex nature of many diseases and conditions, the role of multicomponent 
botanical preparations may increase. Diabetes mellitus is a serious chronic, progressive disease 
characterized by hyperglycemia, which is associated with a variety of comorbidities because 
of considerable damage, dysfunction and failure of multiple organs developed through the 
disease’s progression. Multidisciplinary collaborative research that encompasses innovative 
tools could be used for effective development of new comprehensive therapeutic products 
and treatments based on knowledge of traditional medicine and supported by contemporary 
scientific validation. Conclusion: Comprehensive analysis of Avicenna’s 1,000-year-old 
approach to the treatment of prediabetes and diabetes provides valuable directions in the 
search for plant-based treatments. Botanical therapeutics may provide relatively inexpensive 
and safe methods for diabetes treatment. 
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Introduction
Pancreatic β-cell dysfunction and insulin resistance in target 
organs are the major characteristics of type 2 diabetes mellitus 
(T2DM), the disease that causes profound psychological and 
physical distress in patients and puts an enormous burden 
on health-care systems. Recent advances in understanding 
comprehensive molecular and physiological mechanism 
of glucose metabolism regulations and insulin resistance 
causalities opened new opportunities in search for anti-diabetic 
therapeutics and life-style modifications. With conventional 
treatment strategy shifting from single-component drugs aimed 
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of life lost [1]. In this article, we review current approaches to 
diabetes treatment and prevention and explore how Avicenna’s 
views may help in managing the modern T2DM epidemic. 
Materials and Methods
This review is based on a thorough analysis of the literature in 
English, Russian, Arabic, and Tajik. The appropriate searches were 
conducted in Google Scholar (scholar.google.com), PubMed 
(www.ncbi.nlm.nih.gov/pubmed), KiberLeninka (cyberleninka.
ru), eLIBRARY (elibrary.ru). We also used materials available 
at the Russian National Library (Moscow, Russia) and Central 
Agricultural Science Library (Moscow Russia). The Institute of 
Avicenna’s Medicine and Pharmacology (Dushanbe, Tajikistan) 
and the Institute of Philosophy, Political Science and Human 
Rights of the Academy of Sciences of the Republic of Tajikistan 
graciously provided access to the books authored by Avicenna.
Results
1. Diabetes
Diabetes mellitus (DM), often referred to as simply diabetes, is
a serious chronic, progressive disease characterized by elevated
levels of serum glucose (hyperglycemia) (Figure 1), which is
associated with a variety of comorbidities, such as blindness,
poor wound healing, erectile dysfunction, kidney failure, heart
disease, etc; caused by considerable damage, dysfunction,
and failure of multiple organs developed through the disease
progression. DM occurs either when pancreatic cells do not
produce sufficient amount of insulin, or when the cells of the
body do not respond properly to the produced insulin. Globally,
DM caused over 1.5 million deaths in 2012 and an estimated
8.5% of the adult population (422 million people) were living
with diabetes in 2014 with 30.3 million people or 9.4% in the
US in 2015 [7, 8]. Out of three generally recognized DM types
(type 1 or “insulin-dependent diabetes,” type 2 or “non-insulin-
dependent diabetes,” and gestational diabetes), type 2 (T2DM)
is the most prominent constituting about 90% of all cases.
T2DM is a growing healthcare burden primarily due to long-
term complications. Acute complications can include diabetic
ketoacidosis, nonketotic hyperosmolar coma, or even death.
Serious long-term complications include heart disease, stroke,
chronic kidney failure, foot ulcers, and damage to the eyes. For
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at one target to multitherapeutic combinations addressing the 
complex nature of many diseases and conditions, the role of 
multicomponent botanical preparations may increase. The in-
depth analysis of Avicenna’s approach to diabetes treatment in 
combination with contemporary drug development methodology 
leads to streamlining botanical therapeutics development. Novel 
botanical therapeutics are essential for reducing the 
disease burden and T2DM prevention. 
Central Asia is a vast geographic region with a rich history 
whose countries are closely related through its nomadic peoples, 
e.g., the Silk Road, and the Mongol and Russian Empire [1]. 
Abu 'Ali al-Husayn Ibn Abdullah Ibn al-Hasan Ibn 'Ali Ibn Sina 
(980-1037), better known in the western literature as Avicenna, 
influenced multiple generations of physicians. His evidence-
based medicinal methodology, ideas and treatment methods are 
still very popular in Central Asia and make up the foundation 
of Unani medicine. There is growing interest in reassessing 
and conducting a deep analysis of the Avicenna’s medical 
magnum opus – “The Canon of Medicine”  (al-QãnûnfÎ al-
Tibb) [2-4]. Indeed, acceptance of Avicenna’s medicine requires 
understanding of his medical system, avoiding misunderstandings 
linked to improper translations or misinterpretations, adopting 
practices and recognition of the evidence-based medicine 
practiced millennia ago [2, 4]. “The Canon of Medicine” of 
Avicenna, originally written in Arabic, is a very well-structured 
source of many theoretical and practical branches of medieval 
medicine, and a repository of ideas, many of which remain not 
completely decrypted and may be relevant to modern medicine 
[5, 6]. After the translation and publication of “The Canon of 
Medicine” in Latin, English, Russian, Tajik, Persian, Uzbek and 
many other languages, this magnum opus has reached millions 
of readers. This encyclopedic work is not easy to comprehend 
and it is still full of unsolved and not yet deciphered secrets. 
Translation and interpretation of the medieval Arabic text are 
substantial problems and require not only exceptional language 
skills and an understanding of ancient medical practices, but 
also a broad knowledge of modern science. Unfortunately, 
English translations did not use the original Arabic text, but they 
were done from other translations (Latin, Urdu, and Farsi) and 
failed to capture the spirit of the book [2]. It is also important to 
emphasize that in 2012 non-communicable diseases including 
diabetes have been the highest-ranking causes in Central Asian 
countries in terms of disability-adjusted life years and years
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example, among adults in China, diabetes was associated with 
increased mortality from a range of cardiovascular and non-
cardiovascular diseases. The prevalence of diabetes in China has 
more than quadrupled in recent decades, with an estimated 110 
million adults having diabetes in 2010 and 490 million adults 
estimated to have prediabetes [9]. The Republican Clinical 
Endocrinology Center reports 37,691 people officially diagnosed 
with diabetes in Tajikistan in 2016, with disease prevalence 
for different districts ranging from 280 to 678 per 100,000 
population. In Mongolia, T2DM is growing problem and a 
generally poor glycemic control in patients has been reported 
[10]. It is estimated that worldwide by 2040 one in 10 adults 
will have diabetes [11].
2. History of T2DM and the burden of the disease
Diabetes, in all likelihood, has been recognized as a dangerous
metabolic disorder long before it was first mentioned in the
Ebers papyrus that provides a comprehensive list of diseases
known during the 18th Egyptian dynasty (c. 1630–1350BCE).
Descriptions of diabetes have been found in ancient Indian and
Chinese medical literature, as well as in the work of ancient
Greek and Arab physicians, and in the works of Avicenna (980-
1037), who also described complications like sexual dysfunction
and gangrene [12-14]. Diabetes was known under different
names including the “pissing evil” in the 17th century. The term
“diabetes” was probably coined by Apollonius of Memphis
around 250 BC from Greek origin meaning “go or pass through.” 
Diabetes and Avicenna
Figure 1. T2DM is a complex multisystem disease comprising numerous metabolic defects that contribute to the development of hyperglycemia.
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Diabetes is first recorded in English, in the form “diabete,” in a 
medical text written around 1425. The English anatomist and 
physician Thomas Willis (1621-1675) is attributed with adding 
Latin “mellitus (honey-like, sweet) to Greek “diabetes”–siphon, 
to pass through—to better reflect one of the major diagnostic 
parameters of the condition—excessive sugar in urine [14].
T2DM is a complex multisystem disease comprising 
numerous metabolic defects that contribute to the development 
of hyperglycemia (Figure 1). Insulin resistance (IR) in the skeletal 
muscle and liver along with progressive pancreatic β-cell 
degradation are considered the main causes for the development 
and progression of hyperglycemia. However, research in the 
mechanisms of glucose disequilibrium unveiled a very complex 
network of organ and tissue interaction. Dysfunctions in the 
gastrointestinal tract, endothelium, adipose tissue, pancreatic 
alpha cells, brain, and kidneys have been described, and, 
together with insights into the involvement of liver, muscle, and 
β-cells produce a robust picture of T2DM pathology (Figure 1). 
There is a growing understanding of oxidative stress playing 
an important role in the pathogenesis of IR, dyslipidemia and 
metabolic syndrome [15]. As pathophysiologic mechanisms and 
defects continue to be discovered, they offer an expansion of 
potential targets for treatment of T2DM [16].
The specific courses of T2DM development remain unknown 
even though associated risk factors and overall pathogenesis 
have been described at length. IR, decreased sensitivity to 
circulating insulin,is the defining key pathology that triggers 
compensatory hyperinsulinemia and when pancreatic β-cell 
capacity is insufficient to maintain glucose homeostasis, leads to 
the development of T2DM. β-cell failure, along with IR in muscle 
and the liver, represents the core pathophysiologic defects in 
T2DM. A number of pathophysiological abnormalities linked 
to IR development were added to diabetes pathophysiology to 
reflect the complex nature of hyperglycemia (Figure 1). Multiple 
factors are directly linked both to the onset of diabetes and its 
progression, and are targets for T2DM treatment and prevention. 
Recent progress in describing the molecular mechanisms of IR 
significantly improved our understanding of pathways of T2DM 
onset and progression [17].
3. Etiology of T2DM
IR is a primary factor in hyperglycemia a key symptom of T2DM.
Even though the exact causes for the development of T2DM are still 
not very clear, several important risk factors have been identified. 
A combination of inherited, behavioral and environmental 
factors leads to metabolic syndrome and eventually to the T2DM 
onset. Among the key factors are excess body weight, physical 
inactivity and poor nutrition. Ethnicity, family history of diabetes 
(genetics), past history of gestational diabetes, birth weight, 
certain medications, smoking and advancing age also play an 
important role [18]. The identification of novel biologic predictors 
for T2DM and IR may help improve risk assessment and unveil 
causal pathways beyond established genetic and lifestyle-
related factors. Recent advances have made large-scale -omics 
studies possible that have pinpointed several tentative novel 
biomarkers for T2DM, including branched-chain amino acids and 
circulating micro RNAs, Molecular mechanisms of IR are being 
studied at length [19-22]. It has been shown that p53 has the 
capacity to control the expression of metabolism-related genes 
that are important regulators of metabolic pathways, including 
glycolysis, oxidative phosphorylation, fatty acid metabolism and 
mTOR signaling [23]. Intensive research in biomarkers for IR 
has suggested several target candidates, including adiponectin, 
retinol-binding protein-4 (RBP4), chemerin, adipocyte fatty acid-
binding protein, fibroblast growth factor (FGF21), fetuin-A, 
myostatin, interleukin (IL-6), irisin, and ghrelin, all of which 
may play a significant role in determining insulin sensitivity [24-
26]. The elevation in baseline serum uric acid was found to be 
an independent risk factor for gout, hypertension and both IR 
and T2DM [27]. Further, a recent meta-analysis demonstrated 
an association of low-density lipoprotein cholesterol (LDL-C)-
lowering genetic variants in or near Niemann-Pick C1-Like 
1( NPC1L1) and some other genes with a higher risk of T2DM 
[28]. In addition, among the Apolipoprotein A-V (APOA5) gene 
SNPs, the C allele of -1131T>C polymorphism is a risk factor for 
metabolic syndrome [29]. However, it is not clear yet what could 
be gained from adding novel circulating biomarkers and genetic 
markers to traditional T2DM risk factors.
4. T2DM as systemic disease
4.1. Muscles
In muscles, IR is manifested by impaired glucose uptake
following ingestion of a carbohydrate meal and results in
postprandial hyperglycemia. The signal transduction cascade
from insulin receptors to glucose transporter type 4 (GLUT4),
which ultimately is responsible for insulin-stimulated muscle
Mizhgona Sharofova et al.
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glucose uptake, is well understood and includes insulin receptor 
substrate (IRS1) and phosphatidylinositide 3-kinases (PI3K)/
Akt signaling pathway [30, 31]. Elements of this cascade are 
linked to AMP-activated protein kinase (AMPK), glycogen 
synthase kinase-3 (GSK3), and mammalian target of rapamycin 
(mTOR) pathways that play an important role in cell energy 
metabolism [32]. GLUT4 is in the center of glucose uptake by 
skeletal muscles and T2DM is linked to GLUT4 dysfunction or 
reduction in GLUT4 gene expression. IR is strongly associated 
with increased intramyocellular lipid content and inflammation. 
However, specific molecular mechanisms responsible for IR 
onset are still obscure. Molecular mechanisms of the IR include 
a variety of possible pathways interfering with insulin-GLUT4 
signal transduction cascade. One of the best studied is a lipid-
mediated (e.g., diacylglycerols, fatty acids) the IR [22, 33, 34].
4.2. Liver
The liver plays an essential role in glucose metabolism. In 
a normal state, the combination of hyperinsulinemia and 
hyperglycemia maximizes net hepatic glycogen synthesis. In the 
liver, IR is manifested by an overproduction of glucose during 
the basal state despite the presence of fasting hyperinsulinemia 
in response to insulin, following a meal. Insulin is a central 
regulator of the postprandial transition of hepatic glucose 
metabolism from glucose production to glucose storage. Hepatic 
insulin action requires a coordinated relay of intracellular signals 
and includes both direct and indirect mechanisms [22, 35]. It 
was demonstrated that diacylglycerol (DAG)-mediated activation 
of protein kinase C (PKC)ε impairs hepatic insulin signaling, 
reduces hepatic glycogen synthesis and strongly correlates with 
increased glucose production [36]. In addition, substrate flux 
manifested as additional glucose diverted to the liver due to 
muscle IR, leading to de novo lipogenesis and hyperlipidemia 
and FAs being released in adipose lipolysis in white adipose 
tissues, further drive hepatic lipid synthesis and activates hepatic 
gluconeogenesis Acetyl-CoA–mediated activation of pyruvate 
carboxylase, increasing glucose production [22, 37].
4.3. Pancreas
4.3.1. Pancreatic β-cells
IR places a major stress on pancreatic β-cells to enhance their 
secretion of insulin to offset the reduction in insulin action. 
Provided β-cells are able to increase their secretion of insulin 
sufficiently to counter balance IR, glucose tolerance remains 
normal. However, gradually, the β-cells begin to fail and initially 
the postprandial plasma glucose levels and subsequently, the 
fasting plasma glucose concentration begins to rise, leading to 
the onset of overt diabetes [38]. Impairments in β-cell mass and 
in insulin secretion have been reported in numerous studies in 
patients with T2DM [39]. There is a tight relationship between 
the mass of pancreatic β-cells and functional insulin secretion. 
The onset and pace of β-cells failure determine the rate of 
progression of hyperglycemia. A variable combination of loss 
of mass and loss of function appears in T2DM [39]. The β-cells 
mass remains constant during adulthood, indicating that β-cell 
turnover is limited in humans. Recent studies have suggested 
that there is an increase in β-cell neogenesis in humans with 
obesity, pregnancy and impaired glucose tolerance; however, the 
extent of its contribution to β-cell mass remains unclear [40]. 
By the time a diagnosis of diabetes is made, the patient has 
lost over 80% of his/her β-cell function, and it is essential that 
the physician intervenes aggressively with therapies known to 
correct pathophysiological disturbances in β-cell function [41].
4.3.2. Pancreatic α-cell.
In T2DM subjects, dysregulation of the pancreatic α-cell activity, 
linked to abnormal sensitivity to glucose with less suppression 
during hyperglycemia, leads to the elevated basal plasma 
glucagon concentration and in the increased basal rate of 
hepatic glucose production [41]. Thus, in diabetic subjects with 
persistent fasting hyperglucagonemia, postprandial hepatic 
glucose production remains elevated at fasting levels rather than 
making the rapid postprandial decline typical of nondiabetic 
subjects. Glucagon excess, rather than insulin deficiency, may be 
essential for the development of diabetes. Suppressing glucagon 
action should effectively decrease the long-term complications 
and metabolic derangements of diabetes, enhancing the 
quality of life of diabetic individuals [42]. Glucagon is the 
chief secretory product of α-cells and has been the principle 
measure of α-cell function. Dysregulated glucagon secretion 
plays an important role in the pathogenesis of T2DM. Glucagon 
secretion is normally downregulated by high glucose levels, 
insulin, amylin, somatostatin and glucagon-like peptide 1 (GLP-
1) [43]. Physiological effects of glucagon are defined by its
hypoglycemic counter regulation and include increased hepatic 
glucose production, reduction of glucose oxidation and rapid 
Diabetes and Avicenna
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mobilization of stored glucose for export to the circulation. Also, 
glucagon mediates the enhanced rates of hepatic lipid oxidation 
characteristic of fasting, effects that were due to G-protein-
coupled glucagon receptor activation of peroxisome proliferator-
activated receptor alpha (PPARα) and p38MAPK signaling to 
increase the expression of enzymes involved in β-oxidation 
[44]. Accelerating lipid oxidation provides energy for glucose 
anabolism. It is well-established that in states of poorly controlled 
diabetes with severe insulin deficiency or ketoacidosis, plasma 
glucagon concentrations are extremely high and that failure to 
suppress fasting levels of glucagon after eating contributes to 
hyperglycemia [45, 46]. With clinical studies underway, it has 
become apparent that suppression of glucagon secretion or 
antagonization of the glucagon receptor constitutes potentially 
effective treatment strategies for patients with T2DM [43, 47].
4.4. Gastrointestinal tract 
The incretin effect refers to a well-established fact that glucose 
administered orally elicits a significantly greater insulin response 
compared to an intravenous glucose infusion. The join action 
of two insulinotropic intestinal peptides, glucagon-like peptide 
(GLP-1) and gastric inhibitory polypeptide (GIP), is responsible 
for the incretin effect and a decrease in blood glucose levels 
[48]. The gut hormones, GLP-1 and GIP, secreted respectively 
from the intestinal L-cells and K-cells, account for up to 70% 
of insulin secretory responses after nutrient ingestion [49]. 
In addition, GLP-1 is known to be a physiological inhibitor of 
glucagon secretion, while GIP can stimulate glucagon secretion 
[50]. Growing evidence suggests that GLP-1 promotes fatty acid 
oxidation, reduces lipogenesis in the liver and may increase 
hepatic glucose uptake [51, 52]. Furthermore, the postprandial 
release of GLP-1 might alter reward processes in the orbitofrontal 
cortex, thus exerting satiety effects [53].
4.4.1. Gut microbiome
A rapidly mounting body of evidence shows that gut microbiota 
plays an important role in the development of IR [54]. Recent 
microbiota transplantation studies from insulin resistant donors 
to germ-free animals indicate the causal effect of microbiota [55, 
56]. There is an intensive biochemical and immune “crosstalk” 
between gut microbiota and the host [57, 58]. On the one 
hand, gut microbiota may contribute to host IR in various ways, 
including host appetite, energy balance, fat storage, low-grade 
inflammation etc, [59]. On the other hand, the genetics and 
health condition of the host can shape gut microbiota [56, 60]. 
Human genes, microbial genes, and diet share a complicated set 
of interdependencies [61, 62]. The gut microbiome may be an 
important target for the management of T2DM [63].
4.5. Kidneys
Our understanding of T2DM has been enhanced significantly 
by recognition of the role of kidney glucose transporters in 
regulating plasma glucose levels and producing hyperglycemia.
In individuals with normal glucose tolerance and a mean day 
long plasma glucose concentration of 100 mg/dl, all glucose 
is reabsorbed via sodium–glucose cotransporters SGLT1 and 
SGLT2 located in proximal tubule; hence no glucose is excreted 
in the urine [64]. While the SGLT2 is strictly localized in kidneys, 
the SGLT1 also is expressed in the gut, heart and lungs [64]. In 
healthy individuals, glucosuria may start at the plasma glucose 
levels of 180 mg/dl. Kidney adaptive reaction to a high level of 
glucose in the glomerulus is to conserve glucose by increasing 
glucose reabsorption through upregulation of SGLT2 expression 
and increased glucose transport capacity in T2DM subjects. This 
contributes to persistent hyperglycemia. The maximum glucose 
transport capacity (Tm ) of the proximal tubule on average is 375 
mg/min, which roughly corresponds to 300 mg/dl plasma glucose 
level. In T2DM subjects, all of the filtered glucose in excess of the 
Tm is excreted in the urine [64-66]. Because sodium and glucose 
are cotransported in renal proximal tubular cells, T2DM subjects 
have an increase in total body sodium content and a high risk 
of hypertension [67]. Inhibition of SGLT-2, which is responsible 
for approximately 90% of renal glucose reabsorption, 
increases urinary glucose excretion and lowers blood glucose 
concentrations. SGLT-2 inhibitors improve glycemic control, 
reduce body weight and blood pressure, and are associated 
with a low risk of hypoglycemia [68]. In clinical trials, an SGLT2 
inhibitor (empagliflozin) was found to have a profound effect 
in reducing cardiovascular and all-cause mortality in patients 
with T2DM and antecedents of cardiovascular disease [67]. This 
effect, however, was attributed mostly to a hemodynamic rather 
than a metabolic effect in part due to osmotic/diuretic effect 
of the SGLT2 and to the reduction in arterial blood pressure. 
Adverse events associated with SGLT-2 inhibitors include mild 
to moderate urinary tract and genital infections and mild 
dehydration, potentially leading to orthostatic hypotension [69].
Mizhgona Sharofova et al.
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4.6. Brain
The brain is an insulin-sensitive organ [70]. Insulin can cross the 
blood-brain barrier and the insulin receptor β is highly expressed in 
neurons in different brain regions [71]. Significant changes occur 
in the brain signaling systems regulated by insulin, insulin-like 
growth factor (IGF-1), leptin, dopamine, serotonin, melanocortins 
and GLP-1 even at the early stages of T2DM [72]. Also, there is 
a growing understanding of the role that the low-density lipoprotein 
receptor-related protein 1 (LRP1) may play in the regulation of insulin 
signaling and glucose metabolism [73]. Insulin also acts on the 
brain, which independently suppresses lipolysis by suppression of 
sympathetic outflow and increases triglyceride secretion from the 
liver through yet unknown mechanism [37].The brain is implicated 
in T2DM onset and pathology through a neuroendocrine network of 
appetite suppression and regulation of numerous metabolic processes 
[74]. The absolute majority of obese subjects either developed 
or have a very high risk of developing T2DM [75]. It is known 
that obesity results in the brain becoming resistant to a number 
of satiety-inducing hormones, including insulin and leptin [76-
77]. Both insulin and GLP-1 decrease activity in the orbitofrontal 
cortex and synergistically contribute to the regulation of regional 
brain activity in the postprandial state [53]. Insulin regulates 
activity within many eating behavior-relevant regions, including 
areas of occipital and prefrontal cortical regions, hypothalamus, 
midbrain, brainstem, and regions within the striatum [76]. In 
addition, insulin modulates cognition, body weight, whole-
body glucose, energy, and lipid metabolism [70, 78]. Metabolic 
abnormalities that characterize insulin-resistance syndrome 
may be at least partially associated with modulation of central 
melanocortinergic neurons that have a major impact on visceral 
adiposity and peripheral and hepatic insulin actions [79]. It is 
recognized that the functional state of the brain-signaling 
systems plays an important role in etiology and pathogenesis 
of T2DM and metabolic syndrome (MS). The pharmacological 
approaches controlling the brain-signaling systems regulated by 
insulin, IGF-1, leptin, dopamine, serotonin, melanocortins and 
GLP-1can be regarded as a promising way to treat and prevent 
these diseases and their complications [72].
4.7. Adipose tissue
It widely recognized that adipose tissue, in addition to being a 
primary storage of energy, plays a very important role in body 
metabolism primarily through adipocyte-macrophage interaction, 
releasing adiponectin, FA and the hormone leptin [80-82]. With 
only about 10% total systemic glucose uptake, adipose tissue 
may play only a minor quantitative role in postprandial glucose 
metabolism. On the other hand, growing evidence implicates 
unbalanced adipocyte metabolism and altered fat topography 
in the pathogenesis of glucose intolerance in T2DM [83]. Insulin 
suppresses adipose lipolysis hence reducing glycerol delivery to 
the liver and also lowering hepatic Acetyl-CoA content. Insulin 
also regulates basal lipoprotein lipase expression and activity of 
a number of other proteins [35, 37, 84]. Visceral fat deposition is 
the seminal factor that ultimately causes IR and the detrimental 
inflammatory and hormonal profile that contributes to increased 
risk for cardiovascular disease. Adipocyte hypertrophy and 
other poorly understood factors set off a pathologic adipocyte-
macrophage crosstalk (Cusi 2010) resulting in adipocyte IR 
and the chronic release of FFA with toxic effects (lipotoxicity) 
in distant tissues such as muscle, liver, and pancreatic β-cells 
as well as on the heart and vascular bed [37, 85, 86]. However, 
10% to 45% of the adult obese population is represented by 
the metabolically healthy obese individuals who possess a 
unique subset of characteristics that reduce metabolic and 
cardiovascular risk factors despite the presence of excessive fat 
mass [75].
4.8. Endothelium: macro- and microvascular 
complications
In healthy individuals, the endothelium regulates a complex 
balance of factors that maintain vascular homeostasis and 
normal arterial functions, including cellular adhesion and vessel 
wall inflammation in addition to maintaining vasculogenesis, 
and angiogenesis [87]. Changes in endothelium functions are 
implicated in microvascular complications, such as retinopathy, 
neuropathy and nephropathy. A shift in the functions of the 
endothelium towards vasoconstriction, proinflammatory and 
prothrombic states characterizes the disruption of the normal 
performance of endothelial cells, leading to endothelial 
dysfunction, which is implicated in the pathogenesis of many 
diseases including diabetes [88]. The last three decades of 
the Steno hypothesis development and recent discoveries in 
the field advanced deep understanding of the pathogenesis, 
manifestations and sequelae of global dysfunction of the vascular 
endothelium in diabetes mellitus [89, 90]. The hyperglycemia 
condition of endothelial cells, by inducing elevation of DAG, 
Diabetes and Avicenna
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activates PKC pathway resulting in increased oxidative stress 
[15, 88]. A complex array of factors is associated with the 
pathogenesis of endothelial dysfunction [87]. Even that causality 
may be not very well established; multiple pathways leading to 
microvasculopathy, have been characterized. They include the 
endothelial nitric oxide synthase (eNOS) uncoupling and NO 
deficiency, oxidative and nitrosative stress, lysosomal membrane 
permeabilization and sirtuin 1 (SIRT1) deficiency, increased 
production of inﬂammatory factors, abnormal angiogenesis, 
premature senescence of endothelial and endothelial progenitor 
cells, and disintegration of endothelial glycocalyx have been 
characterized [90]. There is growing interest in the modulatory 
role of microRNAs in diabetes-induced vascular dysfunction 
[87, 90]. A combination of systemic inflammation and the 
presence of high blood glucose concentrations is able to impair 
the vascular endothelium in its function, thus predisposing 
one to atherosclerotic disease. The enhanced oxidative stress, 
the increased circulating free fatty acids and the altered lipids 
metabolism induce heart structure damages that can also lead 
to diabetic cardiomyopathy [15, 91].
5. Contemporary treatment options for T2DM
There is an intense focus on the evidence base for optimal T2DM 
management with the ability to deliver effective multidisciplinary 
care after early diagnosis and initiate effective glucose-
lowering therapies supported by structured education and self-
management programs [92].The European Association for the 
Study of Diabetes and American Diabetes Association adopted a 
patient-centered approach that includes optimizing therapeutic 
options across the life span - the Chronic Care Model (CCM) 
for prevention and treatment of T2DM. A major barrier to 
optimal care is a delivery system that is often fragmented, 
lacks clinical information capabilities, duplicates services, and is 
poorly designed for the coordinated delivery of chronic care 
[93]. The CCM has been recognized as an effective framework 
for improving the quality of diabetes care, emphasizing the 
roles of the health care delivery team and promoting self-
management on the part of the patient [93]. Lifestyle 
changes, which may include setting physical activity and weight 
loss goals, remain the initial intervention for T2DM and Medical 
Nutrition Therapy has become an integral component of 
T2DM prevention, management, and self-management 
education [94]. First-line therapy, involving metformin along 
with lifestyle modification (diet, exercise, and weight loss), is 
typically low cost. However, many patients fail to meet glycemic 
targets on this regimen and require treatment intensification 
[95]. Current glycemic recommendations recognize A1C 7.0% 
(53 mmol/mol), preprandial capillary plasma glucose 80–130 
mg/dL (4.4–7.2 mmol/L), and peak postprandial capillary plasma 
glucose,180 mg/dL (10.0 mmol/L) for nonpregnant adults with 
diabetes.
5.1. Pharmacological therapy for T2DM
Although prevention of T2DM is the ideal solution and has been 
shown to be cost-effective in modeling studies, providing optimal 
cost-effective treatment to those with T2DM is an urgent medical 
need [95]. Given that the high costs of managing T2DM are 
driven in large measure by complications that are a consequence 
of poor glycemic control, the goal for T2DM patients is to attain 
and maintain glycemic control. Research shows that intensive 
blood glucose control can reduce the risk of T2DM complications 
and the cost of managing these complications over periods from 
10 years to a lifetime [95].The current approach to management 
of T2DM is based on the escalation of intervention based on 
patient response and success in glycemic control. In a recent 
meta-analysis, it was found that among adults with T2DM, there 
were no significant differences in the associations between any 
of nine available classes of glucose-lowering drugs (alone or in 
combination) and the risk of cardiovascular or all-cause mortality. 
Metformin was associated with lower or no significant difference 
in HbA1C levels compared with any other drug classes. All 
drugs were estimated to be effective when added to metformin 
[96]. Hence, metformin, if not contraindicated and if tolerated, 
remains the preferred initial pharmacological agent for T2DM 
[93, 96, 97]. However, if noninsulin monotherapy at maximum 
tolerated dose does not achieve or maintain the HbA1C target 
over three months, dual and triple therapy may be used with 
combinational injectable insulin therapy considered when blood 
glucose is 300–350 mg/dL (16.7–19.4mmol/L) and/or HbA1C 
is10–12% (86–108 mmol/mol) [93]. The pharmacological and 
therapeutic implications of current drugs for T2DM were recently 
extensively reviewed [98, 99].
5.2. The need for new therapeutic agents
A recent study demonstrated that among adults with type 2 
diabetes diagnosed for less than 10 years, a lifestyle intervention 
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compared with standard care had only limited success and 
resulted in a change in glycemic control that did not reach 
the criterion for equivalence [100]. New technologies and 
therapeutic options for T2DM patients are being extensively 
investigated [92]. Well-tolerated treatments that produce 
a long-lasting impact on IR are in great demand. Owing 
to better understanding of the pathogenesis of IR and the 
network of the insulin signaling pathway, as described above, 
several pharmacological agents have been developed to treat 
IR. Currently available treatments such as biguanides and 
thiazolidinedione are effective, but their impact may not be 
sustained and they have considerable adverse event profiles. 
Many treatments in development, which target different aspects 
of the insulin-signaling pathway, did not progress beyond 
preclinical development; others that reached clinical trials had 
significant adverse events and/or modest efficacy. In addition, 
the treatments must be specific and reversible, as many of the 
components of the insulin-signaling pathway are involved in 
other cellular functions, such as apoptosis. Despite their efficacy 
in treating IR, lifestyle interventions have not been embraced by 
patients and bariatric surgery has become quite common as a 
treatment option for patients with obesity [101]. There is a great 
need for developing a cluster of new therapeutic agents that will 
provide safe and sustainable improvement in IR and/or prevent 
comorbidities associated with T2DM. Multicomponent botanical 
therapeutics may play an important role in developing this type 
of agents.
6. An approach to utilize Avicenna’s heritage in the
modern world.
Avicenna remains one of the highest medical authorities for the
Central Asian population. His philosophy, including a general
approach to human health and healing, has a profound effect on
practicing medicine by traditional healers and medical doctors
alike. There are two major, sometimes interrelated, approaches
for utilizing Avicenna’s heritage: practicing the traditional Unani
system of medicine and developing novel therapeutic agents.
The Unani system of traditional medicine has been used for
centuries and even though some of the practice success may be
attributed to a placebo effect, it remains an important part of
the health care system, particularly in rural areas of Afghanistan, 
Pakistan, India, Tajikistan, Mongolia, Uzbekistan, and other
Central Asian countries. On the other hand, incorporating
evidence-based healing approaches into contemporary medical 
and pharmacological practices is a comprehensive multifaceted 
process [102]. This process requires an in-depth understanding of 
philosophy and evidence-based medicine practiced by Avicenna. 
Interpretation of the ancient Arabic text is a challenging 
problem and requires a combination of remarkable language 
skills, understanding of medieval medical practices and broad 
knowledge of modern science. One of the coauthors of a current 
paper (Yusuf Nuraliev) is a practicing physician and clinical 
pharmacologist and is also fluent in Arabic. He served as a 
scientific consultant for the latest translation of Avicenna’s books 
to Russian (Dushanbe 2005 – 2015). In the course of his reading 
“The Canon of Medicine”, he noticed that previous Russian 
translations of chapters devoted to diabetes recommended 
using “laxative remedies” that very much contradict the general 
understanding of disease progression and symptoms both from 
Avicenna’s and modern points of views. Further analysis unveiled 
that the Arabic phrase “cleansing “wujud” (existence or inside) 
was interpreted as “laxative effect” or “laxative remedy.” Indeed, 
the phrase should be interpreted as cleansing the “inside” of 
the organism and, most likely, could be linked to repairing the 
function of the endothelium [3] (Figure 1). The difficulties of 
translation and interpretation are particularly acute through the 
chapters devoted to chronic diseases and disorders including 
diabetes. It is not surprising that Avicenna’s writing is still full 
of undiscovered secrets. It is necessary to combine any recent 
scientific research on Avicenna pharmacology, identification of 
medicinal plants and method of preparation. Some of the herbal 
preparations have been used for a long time and a have good 
safety record. It is possible to streamline botanical therapeutics 
leads identification and pharmaceutical development by effective 
use Avicenna’s heritage. In addition, complex medieval botanical 
preparations and individual medicinal plants can be tested 
against multiple new targets identified by modern science. Those 
botanicals can be effectively incorporated in different steps of 
the contemporary drug development process, including discovery 
and development, preclinical and clinical research, regulatory 
approval and post-market monitoring. 
7. Role of medicinal plants in diabetes treatment and
prevention
Though there are various pharmaceuticals available for
prevention of metabolic syndrome and treatment of diabetes,
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herbal formulations are often preferred due to low cost, fewer 
side effects and longer shelf life [103]. This trend is especially 
visible in countries with populations with a limited income 
and well-established practice of traditional medicine such as 
Tajikistan, India, Iran, Saudi Arabia, China and others [104-108]. 
There are attempts to validate the traditional use of medicinal 
plants using contemporary scientific methods [109-111]. 
Multiple plant species used in traditional medicine in different 
parts of the world have been shown to have at least some 
antidiabetic activity [112]. A considerable number of plants was 
subjected to clinical trials and found effective. Moreover, during 
the past few years, many bioactive phytochemicals have been 
isolated from hypoglycemic plants [113, 114].
Multiple mode of actions were suggested for antidiabetic 
medicinal plants. For example, antidiabetic actions of cocoa 
flavanols might contribute to prevention or delay in T2DM onset 
by modulating insulin secretion in pancreatic cells and targeting 
insulin-sensitive tissues because of their insulin-like activity or 
through the regulation of key proteins of the insulin-signaling 
pathways. Cocoa flavanols have been proved to enhance glucose 
uptake through the promotion of glucose transport, to repress 
glucose production, or to improve lipid metabolism [115]. Thirty-
five plant species traditionally used by the indigenous peoples 
of the boreal forest in Canada for three or more symptoms of 
diabetes or its complications demonstrated high free-radical 
scavenging activity [116]. Grape polyphenols protect against 
metabolic syndrome by acting in the intestine to modify gut 
microbial community structure, resulting in lower intestinal and 
systemic inflammation and improved metabolic outcomes [63].
8. Unani system of medicine practiced by Avicenna
In the Unani system of medicine, practiced by Avicenna, a
physician (healer) initially determined features of “mizaj” of a
healthy person, then its changes in diseases, as well as “mizaj”
of medicines, which are prescribed to correct the disease
“mizaj.” The mizaj was often translated as a “temperament”
or sometimes as “nature” [3]. The person’s mizaj consists of
the balanced interaction of the four conflicting principal forces/
qualities (hotness, coldness, dryness and moisture) within the
elements (earth, air, water, fire) [2, 117, 118]. There are four
humors (also translated as “fuel” or “juices”) in the body:
blood (dam); phlegm (balgham); yellow bile (safra); and black
bile (sauda), each of which is associated with a pair of qualities:
hot and moist, cold and moist, hot and dry, and cold and dry, 
respectively. These humors form sanguineous, phlegmatic 
(serous), bilious (red bile), and melancholic (atrabilious) (black 
bile) humors (akhlat) in the body. Each individual has a dominant 
and subdominant temperament with all these humors existing in 
each individual’s body. 
The mizaj of a healthy person is considered as «motadil» 
- neutral or calm when all four properties of hotness, coldness,
dryness and moisture are in harmony and proportional quantity
inherent to a particular individual or organ. “Sue mizaj” or
dystemperament is the deficiency and decrease in the physiologic 
action and reaction of the body, in a way that disturbance and
dullness happen in its chemical action. Avicenna described 16
distinct types of disorders of temperament (called by names
such as sue mizaj, inequable temperament, intemperament,
dyscrasias), which cause sue mizaj gheiremotadil, or imbalance
in the body.
Treatment is aimed directly at restoring balance or 
equilibrium of various elements, humors and faculties to the 
patient’s temperament or humors. Individualized treatment relies 
on the psychophysiological physique of the patient. Avicenna 
states, “Truly, when the quality of the disease is understood, 
it is necessary to choose a medicine with the opposite quality, 
for the disease is treated with opposition”[118]. The physician’s 
task was to restore the balance of disturbed mizaj to the level 
of «motadil», i.e. “balanced nature” by means of suitable 
medications. A single drug should not be used to treat one and 
the same disease. Indeed, Avicenna warned that when treating 
diabetes, one should not take the same medicine with long (and 
repeated courses) treatment. The treatment must include the 
six factors to ensure that, not only are the symptoms treated, 
but the causes of illnesses are also focused upon. While modern 
medicine often aims at controlling symptoms and managing 
illnesses, the Unani system of medicine aims at curing illnesses 
and managing health [117]. Different ideas about treatment, or 
ilaj, introduced in traditional medicine, are grouped asilaj-bil-
Tadbeer (regimental therapy), Ilaj-bil-Ghiza (dietotherapy), Ilaj-
bilDawa (pharmacotherapy) andIlaj-bil-Yad (surgery) [117].
9. Methods of diabetes treatment used by Avicenna
Ethnobotanical studies in Central Asia report that the local
population still broadly uses medicinal plants in treating T2DM
[119]. Many modern folk healers and even physicians, involved
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in the treatment of diabetes, keep secret the remedies and 
therapy methods used for the management of the disease. If 
asked what they use to treat diabetes, the healers usually do not 
provide direct answers or just say that they use techniques of 
Avicenna or other well-known ancient authorities.
For the purpose of this article, we mostly concentrated on 
the materials from“The Canon of Medicine” and the treatise Al-
Vohiya or Faiziya (from the Arabic word”vohiya”orcode and from 
the Tajik word “faiziya” or good) —”Code of Recipes” or “Useful 
Recipes.” The latter work presents a kind of pharmacotherapeutic 
guide for the use of simple medicines, depending on the character 
of their therapeutic effect manifestations in the treatment 
of certain diseases [4, 120]. Avicenna used in “The Canon of 
Medicine” techniques and methods based on advances in the 
scientific and medical terminology of his era. He describes 
cleansing, cooling, decontamination therapy and treatment with 
the principles of “opposite with opposite” and “like with like.” 
Several hundred substances and receipts from different sources 
are mentioned for treatment of different illnesses in the Canon 
[121]. Avicenna described the condition of plant collection and 
storage, which guaranteed the quality of primary materials [122].
Thus far, most medicinal substances prescribed by Avicenna 
remain largely unexamined. When prescribing individual herbal 
remedies, Avicenna often gave only the name of the medicinal 
herb, or the therapeutic form. In some cases, he provided a very 
short description, for example, prescribing the powder from the 
leaves or dried fruits of a particular plant, or from roots of a 
certain tree in a dose of 0.5 or more dirhams, so many times per 
day. A physician unfamiliar with the basics of ancient medical 
terminology does not know how many grams or milligrams 
correspond to 0.5 dirham (about 1.5 gram). In Avicenna’s 
literary works, many recipes provide only the generic name of 
the plant, such as powder from the leaves of mint or oregano.
However, each of these plants includes multiple varieties 
growing in various geobotanical areas on different continents. 
Given these obstacles, only a trained professional can accurately 
select the desired plant species. The medieval medico-biological 
terminology associated with the teaching of mizaj, mizaj-
diagnostics and mizaj-therapy present additional challenges for 
interpreting Avicenna’s approach to treating various diseases. 
Anin-depth analysis of Avicenna’s writings reveals that he 
considered that, in diabetes, the character of mizaj changes to the 
“cold” side. In modern understanding, this may refer to a shift of 
pH of the body fluids towards acidosis. Under the influence of the 
products with the “cold nature,” according to Avicenna, there is 
a significant change of the mizaj of internal environment to the 
cold, i.e. acidic direction, primary in endothelium, as well as in 
the kidneys and liver, leading to diabetes. Avicenna often defined 
character mizaj of drugs by their organoleptic and physical 
parameters, such as taste, smell, color and consistency. In the 
treatment of patients, he demonstrated a very rigorous approach 
to determining the character of the mizaj of the human body as 
a whole, the character of changes of the patient’s body mizaj, 
as well as the character of the mizaj of prescribed medicines. 
In accordance with the classification in the Unani system of 
medicine, most remedies have a simple nature: hot, cold, dry 
or wet. Combinations of these properties define complex mizaj.
Avicenna describes two different tactics in treating 
patients: “like with like” and “opposite with opposite” [118]. 
According to Avicenna, the therapy tactics “like with like,”i.e. 
treatment of cold acidosis by means of cold acidic agents was 
unacceptable, as it promoted deterioration of the patient [123]. 
Consequently, Avicenna prohibited the prescribing of acidic 
foods and beverages in diabetes, realizing that these foods 
aggravate the shift of patient mizaj to the cold diabetogenic 
side [124]. The therapy tactics “opposite with opposite,”i.e. 
treatment of acidosis status by using alkalizing agents, is the 
basis of diabetes therapy by Avicenna. In the basis of Avicenna’s 
medicinal remedies intended for pathogenic and adjuvant 
(accessory) therapy of different degrees and forms of diabetes 
were vegetables, minerals and animal products with alkalizing 
properties, which fully corresponds to the therapy tactics 
“opposite with opposite”[125].
Avicenna emphasized that mizaj is an inherent property of 
the person and the knowledge of the characteristics of mizaj 
allows to correct its deviations occurring in various diseases 
and to restore health [4]. By Avicenna’s definition, “health 
preservation is achieved by balancing (using) certain things and 
avoiding others. The balance of that what should be withdrawn 
from the body and that what should be held in it. Avoid that 
what generates fatal, bad nature, hot or cold, and that what is 
opposed to the nature (of human) by its special property”[118].
Avicenna identified diabetes in “The Canon of Medicine” 
as an independent disease, having a connection with diseases 
of the kidneys and the liver and the pollution of all liquids of 
the internal environment of the organism, i.e., “wujud.” We 
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believe that in modern medicine, an understanding of wujud is 
consistent with the endothelium, which is recognized today as 
the largest endocrine organ in the body [90].
9.1. Evaluation of the antidiabetic treatments proposed 
by Avicenna
In evaluating Avicenna’s treatment of diabetes, researchers at 
the Institute of Avicenna’s Medicine and Pharmacology (IAMP, 
Dushanbe, Tajikistan) have concentrated on two primary 
characteristics of medicines: the cold mizaj corresponding to 
the manifestation of acidity and hot mizaj corresponding to 
alkalinity. A comprehensive approach is used in an analysis of 
Avicenna’s treatment and prevention of diabetes. To identify 
plants, minerals and animal products suggested by Avicenna for 
diabetes treatment and prevention multiple sources, including 
publications in English, Russian, Tajik and Arabic languages were 
cross-referenced. Every treatment, which is aimed at correcting 
the violated mizaj, in general can be called mizaj-therapy, 
i.e. the predecessor of the modern pathogenical therapy in
pharmacology.
As described above, there are many etiological factors 
contributing to the origin of pre-diabetes and IR, and they often 
are not interrelated. Among those factors, the manifestation of 
acidic properties, eventually contributing to the onset of pre-
diabetes and IR, could be a common trigger [120]. Avicenna 
considered that the sour taste inherent in plants and food 
products is the main indicator of the cold mizaj. He noted that 
the consumption of sour (acidic) foods causes a change of mizaj 
of the human body to the cold (sour, acidic) i.e. diabetogenic 
side. 
A growing pool of evidence suggests that a diet with high 
acid load increases body acidity and may be an independent 
predictor of developing IR and T2DM [126]. Higher acidic 
dietary acid-base load, defined by higher the potential renal 
acid load and net endogenous acid production scores, may 
be an independent risk factor for the development of IR and 
related metabolic disorders [127, 128]. Mild metabolic acidosis, 
measured by plasma lactate, aligns with insulin resistance 
independent of obesity and is induced by short-term increases 
in energy and dietary acid load in healthy humans [129]. In large 
prospective cohort studies, a high dietary acid load was positively 
associated with T2DM risk and found to be independent of other 
known risk factors for diabetes [130-132]. Meta-analysis of the 
three prospective cohort studies further confirmed that, after 
adjustment for other diabetes risk factors, a higher dietary acid 
load is associated with an increased risk of T2DM [133].
In our experiments, supplementation of the diet with a 
daily gavage of 5 ml/kg fresh lemon juice in rabbits for two 
weeks resulted in changes associated with diabetogenesis. 
Blood and urine pH was reduced 6.2% and 16.9% respectively, 
and the glucose level in blood increased 58.1% and HbA1c 
increased 72.3%. In addition to mild acidosis, physiological 
and biochemical changes showed the development of IR and 
associated modifications of liver and kidney functions [124]. We 
also showed that six acidic products included in the diabetogenic 
risk factors by Avicenna have pharmacological and biochemical 
effects on the organism of laboratory animals consistent with 
the development of diabetes [6].
Following his predecessors, Avicenna considered that thirst 
and polyuria are the main symptoms of diabetes, and noted, 
“in the urine of patients with diabetes a substance resembling 
honey to taste.” Antidiabetic agents, which have been used 
during that historical period, mainly were evaluated according 
to the manifestation of their thirst-quenching effect [134, 135].
Pharmacological and biochemical screening conducted at IAMP 
showed that medicinal plants recommended by Avicenna have 
not only thirst-quenching action but also a hypoglycemic effect 
(data not shown). This relationship is also noted by modern 
studies [136].
In the opinion of Avicenna, all dysmetabolic processes in 
diabetes are the result of dysfunctions in the three main organs: 
the endothelium, kidneys and liver. In his doctrine, Avicenna pays 
special attention to developing common drug therapy tactics for 
diabetes, especially onIlaj-bil-Ghiza (dietotherapy). Developed by 
Avicenna the tactic of diabetes therapy encompassed all major 
pathogenic disturbances observed in the kidneys, liver and 
endothelium in the early stages of the disease, i.e. it is focused 
entirely on the elimination of the state of pre-diabetes. 
As an experienced physician practicing evidence-based 
medicine, Avicenna prescribed medication that can correct 
the disorders of water metabolism (thirst-quenching) and 
changes in the cardiovascular and nervous systems, as well as 
the internal organs [137]. Tactics of treatment of diabetes by 
Avicenna targeted correcting the process of diabetogenesis itself 
and impaired renal function and liver, which perform excretory 
functions, i.e. correction of acid-base status. Thus, these therapy 
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tactics restored numerous functions of the endothelium. 
Simple and complex anti-diabetic herbal remedies 
recommended by Avicenna are of particular interest. All 
medicines and medicinal plants are characterized by Avicenna in 
the framework of the mizajdoctrine and in accordance with the 
requirements of the two ancient pharmacological laws—therapy 
tactics “opposite with opposite” and “like with like.” The fact 
that all recommended antidiabetic agents were of natural origin 
is another distinctive feature of Avicenna’s medical tactics in 
comparison with the modern approaches to diabetes treatment. 
Those agents had low toxicity and did not cause adverse effects 
on the liver, kidneys and other internal organs. Moreover, their 
curative effect was aimed at restoring normal organs functions, 
as well as contributing to the purification of body fluids and the 
endothelium.
9.2. Natural products used to treat diabetes
We have compiled a list of medicinal plants, minerals and animal 
products recommended by Avicenna for etiopathogenetic, 
auxiliary and symptomatic treatment of diabetes and related 
diseases. We identified Russian and Latin names of medicinal 
plants recommended by Avicenna as antidiabetic agents. We 
used a combination of medieval and contemporary sources to 
identify plants including the “Tajik Thesaurus Medical Dictionary 
at-Tanvir” of Kamari Bukhari (X century); “Kitab Saydana” 
(Pharmacognosy) of Abu Rayhan Beruni and “Hakoik-ul-adviya” 
(Pharmacopoeia) of Abumansur Muwafaq Ali Hiravi (X century). 
Latin names of 75 medicinal plants were confirmed based on 
the description and cross-referenced in the “International Code 
of Botanical Nomenclature” and multi-volume “Flora of Bulgaria 
and the Soviet Union [138].”We consultedweb-based databases, 
including International Plant Names Index; U.S. Department 
of Agriculture, Agricultural Research Service, Beltsville Area; 
Biodiversity Heritage Library; Royal Botanical Gardens Kew; 
Royal Botanical Gardens Edinburgh; European Environment 
Agency; Integrated Taxonomic Information System; and Tropicos. 
The list of most common antidiabetic plants is presented list of 
plant species most commonly referred by Avicenna for diabetes 
treatment: Acacia arabica (Lam.) Willd., Acacia nilotica (L.) 
Delile, Alhagi maurorum Medik., Aloe vera L., Alpinia 
officinarum Hance,  Althaea officinalis L., Armeniaca 
vulgaris Lam.,  Artemisia L. multiple species, Astragalus 
tragacantha L., Berberis vulgaris L.,  Boswellia carteri 
Birdw., Cerasus vulgaris Mill.,  Chamomilla recutita (L.)
Cinnamomum cassia (L.) J. Presl, Cistus ladaniferus 
Curtis, Citrus limon (L.) Burm. Fil., Commiphora 
myrrha Engl., Coriandrum sativum L., Crocus sativus 
L., Cucumis sativus L., Cucurbita maxima Duchesne, 
Cupressus sempervirens L., Cydonia oblonga Mill., 
Cynara scolymus L., Cyperu srotundus L., Daucus 
carota L., Ecballium elaterium (L.) A.Rich., Ferula 
foetida Regel, Foeniculum vulgare Mill., Geranium collinum 
Stephan ex Willd., Glycyrrhiza glabra L., Hordeum vulgare L., 
Hypericum perforatum L., Iris germanica L., Lactuca scariola 
L., Malabaila pumila Boiss., Matricaria chamomilla L., Mentha 
arvensis L., Nymphaea alba L., Origanum dictamnus L., 
Phaseolus vulgaris L., Pimpinella anisum L., Plantago psyllium 
L., Portulaca oleracea L., Potentilla reptans L. Prunus 
domestica L., Punica granatum L., Pyrus communis L., 
Rhus coriaria L., Rosa cinnamonea L., Rosa damascena P. 
Mill., Silybum marianum (L.) Gaertn., Syzygium aromaticum 
(L.) Merr. & L. M. Perry, Thymus glaber Mill., Triticuma 
estivum L., Triticum vulgare Vill., Viola odorata L., Vitis vinifera 
L., 
The arsenal of medicines that Avicenna recommended for 
diabetes therapy included 84 agents. Plant products accounted 
for 75 items (89.3%), animal six (7.1%), and mineral tree, 
(3.6%). Depending on the natural product properties was 
performed either on herbal infusion (1plant material:10 water), 
or freshly collected sap, or fresh juices (fruits). We measured pH 
and evaluated the concentration of alkaline (potassium, sodium, 
magnesium) and acidic (Cl-, PO4
3-, SO4
2-) equivalents and some 
organic acids. Using these results, we classified all 84 antidiabetic 
herbs and animal and mineral agents in two groups: acidic (cold 
mizaj) and alkaline (hot mizaj). The absolute majority of tested 
substances (92%) belonged to alkaline (hot mizaj). This includes 
allof the mineral and plant products with the exception of the 
fruit juice of two plant species, Rosa cinnamonea L 
(cinnamon rose, pH 1.8-2.8) and Citrus limon (L.) Burm. 
Fil. (lemon, pH around 2.3-3.4). 
The results of the scientific analysis of Avicenna’s doctrine, 
dedicated to the issues of ilaj-bil-Tadbeer, Ilaj-bil-Ghiza and Ilaj-
bilDawa of diabetes, showed that in the first place, A vicenna 
recommended diet correction (Ilaj-bil-Ghiza) and then medicinal 
treatment. Along with simple vegetable, animal and mineral 
remedies (Ilaj-bilDawa), Avicenna used 20 complex products 
consisting of two or more components for the treatment of 
severe forms of diabetes. 
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9.3. Developing botanical therapeutics based on 
Avicenna’s ideas
Our preliminary analysis showed that in ecologically clean 
mountainous regions of Tajikistan, more than 40 species of 
medicinal plants with active metabolism corrective properties, 
including antidiabetic, are growing. Many polyphenol- and 
flavonoid-containing plants have, along with a hypoglycemic 
effect, active hepatoprotective, nephroprotective, antioxidant, 
angioprotective, immunostimulant or adaptogenic effects. 
Therefore, creation of new plant polyphenols containing herbal 
remedies may provide fundamentally new effective antidiabetic 
agents with metabolism-corrective effects, improving liver, 
kidney, and pancreas functioning (Figure 1), as well as actively 
suspending the process of diabetogenesis. Widely distributed in 
Tajikistan,G. collinum is a medicinal plant mentioned by Avicenna 
for diabetes treatment and has been used in traditional medicine 
for the treatment of rheumatism, gout, dysentery, skin wounds, 
eczema and external and internal bleeding. The plant’s total 
polyphenolic compounds 349.84 mg GAE/g, flavonoids 96.07 
mg QE/g, antioxidant activity IC50 11.21 µg/mL, antidiabetic 
activity (PTP-1B) IC50 0.10 µg/mL and (α-Glucosidase) IC50 0.07 
µg/mL were measured using a 50% aqueous-ethanolic extract. In 
addition 10 biologically active compounds were elucidated from 
the root of  G . collinum by analyzing their spectral data (MS, 1H 
and 13C-NMR, including HMQC, HMBC and DEPT): 3,3’,4,4’-
tetra-O-methylellagic acid, 3,3’-di-O-methylellagic acid, caffeic 
acid, quercetin, (+)-catechin, (–)-epicatechin, (–)-
epigallocatechin, gallic acid, β-sitosterol-3-O-β-D-
glucopyranoside and corilagin [114]. 
Within the framework of Avicenna’s approach to diabetes 
management new botanical therapeutics have been developed 
at IAMP. For example, Novobet, a concoction of roots of 
G. collinum, G. glabra and fruits of R. coriaria, inalloxan-
induced diabetic rabbits demonstrated significant activity in 
reducing hyperglycemia. An oral dose of 5 ml/kg 
Novobet infusion resulted, at seven, 15 and 30 days of 
treatment, in serum glucose level reductions, compared with 
untreated animals. In addition, serum concentration of total 
lipids, cholesterol, triglycerides and malondialdehyde decreased 
and HDL level increased [139].
Conclusion and discussion.
Even a millennium later, we have a lot to learn from the 
evidence-based medical approach of Avicenna [3, 6, 117]. A 
conventional, comprehensive approach to the prevention and 
treatment of diabetes relies on a growing understanding of 
glucose metabolism and regulatory pathways (Figure 1). Multiple 
glucose-reducing medicines differ in efficacy, ease of use, 
negative side effects and cost. The potential of a therapy “cost” 
involves more than just a cost-benefit analysis. It is based on 
the set of attributes that takes into account the long-term safety 
and tolerability, risk of hypoglycemia, weight gain and suitability 
of using it in a presence of comorbidities. Individualized therapy 
should take into account the needs and preferences of patients, 
based on their circumstances, their understanding and their 
commitment. Now, as in Avicenna’s times, for tolerant, adequate 
pharmacotherapy, an individual approach is required to assess 
goals of treatment and to achieve them in the safest way. 
Consequently, for the purposes of effective treatment of T2DM 
and prevention of severe complications we need to integrate 
Western and complementary medicines. 
In both in Avicenna’s and contemporary approaches, 
diet plays a major role in the prevention and management of 
diabetes. Plant-based foods such as fruits and vegetables are 
a key source of potassium and magnesium, major contributors 
to the dietary alkali load. Numerous studies have reported 
the putative association of the consumption of specific food 
products, or their constituents, with the incidence of diabetes, 
and mounting evidence now suggests that some dietary factors 
can improve glycemic regulation. Foods and dietary constituents 
have been shown to act through multiple pathways and may 
exhibit a variety of modes of action including inhibition of 
carbohydrate-hydrolyzing enzymes, intestinal glucose transport, 
hepatic glucose output, delay of gastric emptying and/or 
intestinal absorption of carbohydrates [140, 141]. Food products 
and dietary constituents may modulate the incretin effect, 
stimulate glucagon-like peptide-1 (GLP-1) secretion or inhibit 
dipeptidyl peptidase-IV (DPP-IV). Some dietary constituents 
mimic insulin action, affect insulin release or sensitivity, or inhibit 
protein tyrosine phosphatase 1B (PTP1B). They also may activate 
the peroxisome proliferator-activated receptor gamma (PPAR-γ), 
demonstrate insulin mimetic action or stimulate insulin secretion 
[141].
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The majority of medicinal plants have never been tested 
against ever-growing numbers of molecular targets (Figure 1). 
Medicinal plants are multifaceted, adaptive, environmentally 
interactive systems exhibiting synergy and nonlinear healing 
causality [142]. Recently, Western science and indigenous 
science appear as equally valid notions to guide emergent 
research practices [110]. Many herbal medicines are now being 
supported by scientific evidence and have been shown to exert 
significant effects in the body, relieve symptoms, treat disease 
and improve everyday function. Diverse natural compounds have 
been shown to affect cardiovascular and metabolic disorders 
via different mechanisms, such as anti-inflammatory activity, 
improvement of blood lipid profiles, improvement of insulin 
sensitivity, or normalization of blood glucose levels. However, 
only a few molecular targets or pathways are well-established 
to mediate the beneficial effects of natural compounds in the 
context of cardiovascular and metabolic disorders. Selected 
examples include the AMP-activated protein kinase (AMPK), 
cyclooxygenase (COX)-1 and -2, the dipeptidyl peptidase-4 
(DPP-4), eNOS, the transcription factors NF-κB, nuclear factor-
erythroid 2-related factor 2 (Nrf2), and PPAR, the PTP1B, and 
5-lipoxygenase (5-LO) [143, 144]. For a variety of medicinal plants 
used in many traditional medicines, the mechanisms of action 
have not yet been elucidated. Scientists routinely accumulate 
large sets of data produced by advanced technologies. Hence, 
computational approaches and advanced synthetic techniques 
may be effectively utilized in developing botanical therapeutics 
[111].
A recent review summarized that medicinal plants 
used in Persian medicine, including many used by Avicenna 
for prevention and treatment of diabetes performed their 
therapeutic effects via various well-established pharmacological 
mechanisms of actions. Established modes of actions encompass 
multiple cellular mechanisms, including regeneration of 
pancreatic β-cell, limitation of glycogen degradation and 
gluconeogenesis and anti-inflammatory, immunoregulatory, 
antiapoptosis, antioxidative stress, as well as modulation of 
intracellular signaling transduction pathways [145]. In the 
current paper, we also demonstrated how anin-depth analysis 
and new interpretations of the 1,000-year-old text may lead 
to new approaches to the search for diabetes prevention and 
treatment. Naturally, the efficacy of medicinal herbs needs to be 
established, and toxicity, contraindications and side effects also 
need to be investigated.This is best done with clinical research 
and trials that are being conducted almost exclusively on efficacy 
and are limited in number, probably because of a lack of funding. 
Very little to no attention is being given to more traditional fresh 
herbal extracts [146].
It is essential to monitor the quality of botanical therapeutics 
and adapt the use of medicinal plants to modern conditions. 
The quality of the botanicals can be significantly improved 
by implementing good agricultural practices at the point of 
cultivation of medicinal plants and good practices during the 
manufacturing and packaging of finished herbal products, as 
well as post-marketing quality-assurance surveillance [147]. 
Clinical evaluation of botanical therapeutics remains an 
important issue. Collaborative partnerships offer the context and 
process by which many of the ethical challenges in international 
herbal medicine research can be resolved [148]. The Fogarty 
International Center of the National Institutes of Health plays 
an important role in cross-training investigators and investing 
in safety-monitoring infrastructure, which helps promote ethical 
international herbal medicine research. Comprehensive analysis 
of Avicenna’s approach to the treatment of prediabetes and 
diabetes provides valuable directions in the search for plant-
based treatments. Botanical therapeutics may provide relatively 
inexpensive, safe methods for diabetes treatment. This is even 
more important for developing countries with limited resources. 
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